{"id":{"repo_id":"aachen","oai_identifier":"oai:publications.rwth-aachen.de:62773"},"canonical_url":"https://search.dev.ndltd.org/etd/aachen/oai:publications.rwth-aachen.de:62773","repository":{"repo_id":"aachen","name":"RWTH Aachen University","base_url":"https://publications.rwth-aachen.de/oai2d"},"display":{"title":"Neue Methoden der Proteinanalytik zur Identifikation von diagnostisch relevanten Molekülen für das Harnblasen- und Prostatakarzinom","abstract":"Bladder cancer and prostate cancer rank among the three most common urological cancers. Currently, detecting both types of cancer relies on gold standard diagnostic tools (cystoscopy and cytology regarding bladder cancer and serum PSA value, digital rectal examination and histological evaluation of prostate biopsies regarding prostate cancer) which lack sensitivity and specificity. However, an early and reliable diagnose would result in improved patient´s outcome and prognosis, as for cancer in general. Especially patients with bladder cancer need a sometimes livelong sensitive follow up as cancer tends to recidivate. As the proteome is much more complex and dynamic than the genome its analysis holds out the prospect of overcoming some of the limitation of other approaches in the identification of new marker molecules. Therefore tissue, serum and urine samples from patients with bladder and prostate cancer, respectively, were subjected to different proteomic techniques (2D-SDS-PAGE, MALDI- and SELDI-TOF-MS, MALDI imaging). In particular, analysis of magnetic bead based fractioned serum samples of both entities resulted in sensitivity and specificity values above the standard values when comparing both entities among themselves as well as both entities with healthy controls. Tissue analysis of both entities with MALDI imaging showed good results regarding classification. Based upon the results of this study identification of the discovered potential marker molecules could lead to sensitive and valid tests for diagnosis and follow up of bladder and prostate cancer patients.","abstract_html":"Bladder cancer and prostate cancer rank among the three most common urological cancers. Currently, detecting both types of cancer relies on gold standard diagnostic tools (cystoscopy and cytology regarding bladder cancer and serum PSA value, digital rectal examination and histological evaluation of prostate biopsies regarding prostate cancer) which lack sensitivity and specificity. However, an early and reliable diagnose would result in improved patient´s outcome and prognosis, as for cancer in general. Especially patients with bladder cancer need a sometimes livelong sensitive follow up as cancer tends to recidivate. As the proteome is much more complex and dynamic than the genome its analysis holds out the prospect of overcoming some of the limitation of other approaches in the identification of new marker molecules. Therefore tissue, serum and urine samples from patients with bladder and prostate cancer, respectively, were subjected to different proteomic techniques (2D-SDS-PAGE, MALDI- and SELDI-TOF-MS, MALDI imaging). In particular, analysis of magnetic bead based fractioned serum samples of both entities resulted in sensitivity and specificity values above the standard values when comparing both entities among themselves as well as both entities with healthy controls. Tissue analysis of both entities with MALDI imaging showed good results regarding classification. Based upon the results of this study identification of the discovered potential marker molecules could lead to sensitive and valid tests for diagnosis and follow up of bladder and prostate cancer patients.","abstract_has_math":false,"creators":["Schwamborn, Kristina"],"institution":"Publikationsserver der RWTH Aachen University","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["Knüchel-Clarke, Ruth"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2007,"date_issued":"2007","date_published":"2007","updated_at":"2026-07-30T19:43:28Z","subjects":["info:eu-repo/classification/ddc/610","Blasenkrebs","Prostatakrebs","Proteomanalyse","MALDI-MS","Zweidimensionale Elektrophorese","Medizin","SELDI-MS","MALDI imaging","bladder cancer","prostate cancer"],"languages":["ger"],"rights":["info:eu-repo/semantics/openAccess"],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["https://publications.rwth-aachen.de/search?p=id:%22RWTH-CONV-124279%22"],"render_values":[{"text":"https://publications.rwth-aachen.de/search?p=id:%22RWTH-CONV-124279%22","href":"https://publications.rwth-aachen.de/search?p=id:%22RWTH-CONV-124279%22","code":true}]}]},"links":{"outbound_url":"https://publications.rwth-aachen.de/record/62773","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Knüchel-Clarke, Ruth"]},{"key":"dc:creator","label":"Author","values":["Schwamborn, Kristina"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:coverage","label":"Dc Coverage","values":["DE"]},{"key":"dc:date","label":"Dc Date","values":["2007"]},{"key":"dc:publisher","label":"Institution","values":["Publikationsserver der RWTH Aachen University"]},{"key":"dc:relation","label":"Dc Relation","values":["info:eu-repo/semantics/altIdentifier/urn/urn:nbn:de:hbz:82-opus-22627"]},{"key":"dc:type","label":"Dc Type","values":["info:eu-repo/semantics/doctoralThesis","info:eu-repo/semantics/publishedVersion"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["info:eu-repo/classification/ddc/610","Blasenkrebs","Prostatakrebs","Proteomanalyse","MALDI-MS","Zweidimensionale Elektrophorese","Medizin","SELDI-MS","MALDI imaging","bladder cancer","prostate cancer"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["ger"]},{"key":"dc:rights","label":"Dc Rights","values":["info:eu-repo/semantics/openAccess"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://publications.rwth-aachen.de/record/62773","https://publications.rwth-aachen.de/search?p=id:%22RWTH-CONV-124279%22"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Bladder cancer and prostate cancer rank among the three most common urological cancers. Currently, detecting both types of cancer relies on gold standard diagnostic tools (cystoscopy and cytology regarding bladder cancer and serum PSA value, digital rectal examination and histological evaluation of prostate biopsies regarding prostate cancer) which lack sensitivity and specificity. However, an early and reliable diagnose would result in improved patient´s outcome and prognosis, as for cancer in general. Especially patients with bladder cancer need a sometimes livelong sensitive follow up as cancer tends to recidivate. As the proteome is much more complex and dynamic than the genome its analysis holds out the prospect of overcoming some of the limitation of other approaches in the identification of new marker molecules. Therefore tissue, serum and urine samples from patients with bladder and prostate cancer, respectively, were subjected to different proteomic techniques (2D-SDS-PAGE, MALDI- and SELDI-TOF-MS, MALDI imaging). In particular, analysis of magnetic bead based fractioned serum samples of both entities resulted in sensitivity and specificity values above the standard values when comparing both entities among themselves as well as both entities with healthy controls. Tissue analysis of both entities with MALDI imaging showed good results regarding classification. Based upon the results of this study identification of the discovered potential marker molecules could lead to sensitive and valid tests for diagnosis and follow up of bladder and prostate cancer patients."]},{"key":"dc:source","label":"Dc Source","values":["Aachen : Publikationsserver der RWTH Aachen University 142 S. : Ill., graph. Darst. (2007). = Aachen, Techn. Hochsch., Diss., 2007"]},{"key":"dc:title","label":"Title","values":["Neue Methoden der Proteinanalytik zur Identifikation von diagnostisch relevanten Molekülen für das Harnblasen- und Prostatakarzinom"]}]}],"canonical_facts":{"dc:contributor":["Knüchel-Clarke, Ruth"],"dc:coverage":["DE"],"dc:creator":["Schwamborn, Kristina"],"dc:date":["2007"],"dc:description":["Bladder cancer and prostate cancer rank among the three most common urological cancers. Currently, detecting both types of cancer relies on gold standard diagnostic tools (cystoscopy and cytology regarding bladder cancer and serum PSA value, digital rectal examination and histological evaluation of prostate biopsies regarding prostate cancer) which lack sensitivity and specificity. However, an early and reliable diagnose would result in improved patient´s outcome and prognosis, as for cancer in general. Especially patients with bladder cancer need a sometimes livelong sensitive follow up as cancer tends to recidivate. As the proteome is much more complex and dynamic than the genome its analysis holds out the prospect of overcoming some of the limitation of other approaches in the identification of new marker molecules. Therefore tissue, serum and urine samples from patients with bladder and prostate cancer, respectively, were subjected to different proteomic techniques (2D-SDS-PAGE, MALDI- and SELDI-TOF-MS, MALDI imaging). In particular, analysis of magnetic bead based fractioned serum samples of both entities resulted in sensitivity and specificity values above the standard values when comparing both entities among themselves as well as both entities with healthy controls. Tissue analysis of both entities with MALDI imaging showed good results regarding classification. Based upon the results of this study identification of the discovered potential marker molecules could lead to sensitive and valid tests for diagnosis and follow up of bladder and prostate cancer patients."],"dc:identifier":["https://publications.rwth-aachen.de/record/62773","https://publications.rwth-aachen.de/search?p=id:%22RWTH-CONV-124279%22"],"dc:language":["ger"],"dc:publisher":["Publikationsserver der RWTH Aachen University"],"dc:relation":["info:eu-repo/semantics/altIdentifier/urn/urn:nbn:de:hbz:82-opus-22627"],"dc:rights":["info:eu-repo/semantics/openAccess"],"dc:source":["Aachen : Publikationsserver der RWTH Aachen University 142 S. : Ill., graph. Darst. (2007). = Aachen, Techn. Hochsch., Diss., 2007"],"dc:subject":["info:eu-repo/classification/ddc/610","Blasenkrebs","Prostatakrebs","Proteomanalyse","MALDI-MS","Zweidimensionale Elektrophorese","Medizin","SELDI-MS","MALDI imaging","bladder cancer","prostate cancer"],"dc:title":["Neue Methoden der Proteinanalytik zur Identifikation von diagnostisch relevanten Molekülen für das Harnblasen- und Prostatakarzinom"],"dc:type":["info:eu-repo/semantics/doctoralThesis","info:eu-repo/semantics/publishedVersion"]},"updated_at":"2026-07-30T19:43:28Z"}